Our Latest Thinking

We are constantly scanning the health care market for new and interesting developments; then we write about them here. Check out our latest thinking.


Remarkable Growth of Pharmaceutical Distribution Network to Upsurge the Position of Global Biopharmaceutical Third Party Logistics

June 7th, 2019

Digital Journal posted “Remarkable Growth of Pharmaceutical Distribution Network to Upsurge the Position of Global Biopharmaceutical Third Party Logistics,” highlighting the Pharmaceutical Distribution Security Alliance (PDSA) and its proposed system for Drug Supply Chain Security Act (DSCSA) governance.  View the article here.

Read More >

Political Checkpoint: 2019 National Health Policy Agenda

April 18th, 2019

On April 18, 2019, Leavitt Partners hosted a webinar focused on helping you track the most important health policy developments in Washington D.C.  For details and to listen to the recording, click here.  

Read More >

Leavitt Partners Welcomes Elizabeth Wroe to the Firm

March 26th, 2019

Liz Brings to Leavitt Partners Extensive Federal and State Health Care Policy and Strategy Experience. Salt Lake City, March 26, 2019 –Today, Leavitt Partners is proud to announce and welcome Elizabeth Wroe as a principal based in Washington, D.C. Liz will develop and manage complex, multi-sector alliances, and will advise and inform clients on the […]

Read More >

Pharmaceutical Distribution Security Alliance Releases Proposal for Governance of DSCSA Interoperability

March 25th, 2019

Washington, D.C., March 25, 2018 — The Pharmaceutical Distribution Security Alliance (PDSA), a coalition of more than 25 pharmacies, distributors, logistics operators, manufacturers, and associations, committed to strengthening the nation’s pharmaceutical distribution supply chain through implementation of the Drug Supply Chain Security Act (DSCSA), has released a proposal for Governance of DSCSA Phase II Interoperability. […]

Read More >

FDA’s New Pilot Program Encouraging Innovation

December 6th, 2018

The article discusses the Complex Innovative Trial Designs Pilot Meeting Program, and the opportunity for sponsors with an Investigational New Drug.

Read More >

Implications of the 2018 Midterm Elections

November 16th, 2018

Health care was a central issue in this year’s midterm elections. In the days after the election, many have speculated on what the results mean for U.S. health care policy. Since the Republicans maintained control of the Senate, while the Democrats took control of the House, some see the next two years as a time […]

Read More >

A Uniquely American Health System

August 16th, 2018

As the United States continues to move toward a value-based health care system, significant challenges slow down our progress. Political pressure exists from all sides, incentives have yet to be appropriately aligned, and the pressing need to change stakeholder behavior remains a time-sensitive imperative. Solving these challenges requires going beyond admiring the challenges to implementing […]

Read More >

CMS Targets Value-Based Purchasing, Drug Costs to Reduce Spending

May 8th, 2018

A RevCycleIntelligence article entitled “CMS Targets Value-Based Purchasing, Drug Costs to Reduce Spending” references the Leavitt Partners “Accountable Care Organizations and Risk-Based Payment Arrangements: Strong Preference for Upside-Only Contracts” white paper. The article states, “About 61 percent of ACO contracts contain only upside financial risk, meaning organizations do not have to repay financial losses, a […]

Read More >